Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MDNA
DateTimeSourceHeadlineSymbolCompany
05/14/20243:29PMEdgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MDNAMedicenna Therapeutics Corporation
05/14/20242:42PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MDNAMedicenna Therapeutics Corporation
05/13/20241:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/30/20242:07PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/26/20242:28PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/25/20241:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/22/20243:40PMEdgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:MDNAMedicenna Therapeutics Corporation
04/16/20244:05PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MDNAMedicenna Therapeutics Corporation
04/16/20244:05PMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/16/20244:04PMEdgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNASDAQ:MDNAMedicenna Therapeutics Corporation
04/09/20241:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/04/20241:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
02/14/20246:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
01/24/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
01/09/20249:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
01/05/20248:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
12/22/20231:13PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
11/09/20237:56AMGlobeNewswire Inc.Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNASDAQ:MDNAMedicenna Therapeutics Corporation
11/08/20239:29AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
11/06/20236:00AMGlobeNewswire Inc.Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
11/03/202311:00AMGlobeNewswire Inc.Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/27/20236:55AMGlobeNewswire Inc.Medicenna Announces Nasdaq Delisting and Cutback of Management TeamNASDAQ:MDNAMedicenna Therapeutics Corporation
10/25/20232:51PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/25/20236:00AMGlobeNewswire Inc.Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNASDAQ:MDNAMedicenna Therapeutics Corporation
10/24/20236:18AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/24/20236:15AMGlobeNewswire Inc.Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/20237:57AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/20236:07AMGlobeNewswire Inc.Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
10/03/20234:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/03/20236:00AMGlobeNewswire Inc.Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MDNA

Your Recent History

Delayed Upgrade Clock